Product Offers Targeted Relief for Managing Chronic Condition MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 11, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it has received approval from the

Innovative Drug-Device Combination Will Leverage Company’s Expertise in Localized Drug Delivery MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 17, 2018-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced the

New Treatment Is Clinically Proven to Reduce Polyps and Symptoms of Nasal Congestion MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 2, 2018-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced U.S.

MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 11, 2021-- Intersect ENT ® , Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U.S. availability of the new Straight Delivery System (“SDS”) packaged with the

Patrick Broderick to Serve as Executive Vice President, General Counsel and Corporate Secretary, and Reyna Fernandez Named as Chief Human Resource Officer MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 17, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear,